Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

Hepatology

Volumn 47, Issue 1, 2008, Pages 35-42

  Dalgard, Olav ^a,b,c   Bjøro, Kristian ^c   Ring Larsen, Helmer ^d,e   Bjornsson, Einar ^f   Holberg Petersen, Mona ^a   Skovlund, Eva ^g   Reichard, Olle ^h   Myrvang, Bjørn ^a   Sundelöf, Bo ⁱ   Ritland, Ståle ^j   Hellum, Kjell ^k   Frydén, Aril ^l   Florholmen, Jon ^m   Verbaan, Hans ⁿ   Lange, O ^o   Kristiansen, M Gangsøy ^o   Carlson, H ^o   Njod J ^o   Langtind, J ^o   Barstad, S ^o   Karlsen, L ^o   Viggen, B ^o   Henriksen, A ^o   Steinum, H ^o   Melsom, E ^o   Henriksen, T H ^o   Reinertsen, E ^o   Torp, R ^o   Seierstad, H ^o   Hoeg V ^o   Bjornholt ^o   Eskesen, A ^o   Enger, A ^o   Chelsom, J ^o   Hope, O ^o   Paulsen, J ^o   Huppertz Hauss, G ^o   Ringstad, J ^o   Sandvei, P ^o   Haug, J B ^o   Paulsen, E ^o   Noraberg, G ^o   Von Der Lippe, B ^o   Maeland A ^o   Myrvang, B ^o   Dorenberg, D ^o   Oktedalen O ^o   Klinge, K ^o   Lungren, B ^o   Heger, B ^o   Strom F ^o   Olsen, P ^o   Ali, A ^o   Svensson, S ^o   Cardell, K ^o   Carlsson, M ^o   Hacklou, J ^o   Ekvall, H ^o   Hovmoller S ^o   Stjarnholm H ^o   Wendahl, S ^o   Blackberg J ^o   Braconier, J H ^o   Hallgarde A ^o   Inghammar, M ^o   Lind, H ^o   Elvstan, B ^o   Haglund, M ^o   Montelius, ^o   Johansson, A C ^o   Eklund, P O ^o   Blivik, O ^o   Carlsson, T ^o   Hagen, K ^o   Aleman, S ^o   Hultcrantz, R ^o   Fohlman, J ^o   Forsberg, P ^o   Dahl, P ^o   Rahm, ^o   Hanik, L ^o   Elmrud, H ^o   Lindblom, A ^o   Bergkvist, P I ^o   Lindahl, L ^o   Hugo Persson, M ^o   Tuvesson, B ^o   Johansson, B ^o   Larsson, A K ^o   Widerstrom M ^o   Eriksson, G ^o   Lindhardt, B ^o   Weis, N ^o   Kroman Andersen, H ^o   Orholm, M ^o   Moller A ^o   Krarup, H ^o   more..

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d Rigshospitalet   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY OF OSLO   (Norway)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ GÄVLE HOSPITAL   (Sweden)

^j Hospital of Buskerud   (Norway)

^k AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^l Linköping Hospital   (Sweden)

^m UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

ⁿ LUND UNIVERSITY HOSPITAL   (Sweden)

^o NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; ECONOMIC ASPECT; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THYROID DISEASE; VIROLOGY;

EID: 38649090068     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21975     Document Type: Article

References (15)

1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
3. Butt AA, Justice AC, Skanderson M, Rigsby M, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2006;56:358-359.
4. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
5. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-999.
6. Shiffman M, Pappas S, Nyberg L, Greenbloom S, Gibas A, Bacon B, et al. Peginterferon alfa-2a (40KD; Pegasys (R)) ribavirin (Copegus (R)) for 16 or 24 weeks in patients with genotype 2 or 3: final results of the Accelerate trial. J Hepatol 2006;44(Suppl 2):A734.
7. Medeiros-Filho JE, de Carvalho Mello I, Pinho JR, Neumann AU, de Mello MF, da Silva LC, et al. Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy. World J Gastroenterol 2006;12:7271-7277.
8. Neumann AU, Um NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-107.
9. Bjoro K, Bell H, Hellum KB, Skaug K, Raknerud N, Sandvei P, et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol 2002;37:226-232.
10. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. HEPATOLOGY 2003;38:645-652.
11. Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. HEPATOLOGY 2004;40:1260-1265.
12. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005 23;352:2609-2617.
13. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-527.
14. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. HEPATOLOGY 2003;38:518-526.
15. Shiffman M, Pappas SBB, Godofsky E, Nelson D, Harley H, Diago M, et al. Utility of virological response at week 4 and 12 in the prediction of SVR rates in genotype 2/3 patients treated with peginterferon alfa-2a (40 KD) plus ribavirin: findings from Accelerate [Abstract]. HEPATOLOGY 2006; 44(Suppl):A340.